BPC 157 Explored for Corneal Ulcer Healing, Neovascularization, and Glaucoma Management

Corneal ulcers represent a significant challenge in ophthalmology, often leading to vision impairment due to slow healing, secondary corneal neovascularization (the growth of new, abnormal blood vessels into the cornea), and sometimes elevated intraocular pressure (IOP), a key risk factor for glaucoma. Current treatments often target individual aspects, but a comprehensive therapeutic strategy addressing this complex interplay is lacking. This study introduces a novel conceptual framework, the 'Triad' of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and evaluates how pentadecapeptide BPC 157 could simultaneously address these interconnected ocular pathologies.

The study demonstrated significant improvements across all three components of the 'Triad' in the BPC 157 treated group compared to controls. Corneal ulcer healing was markedly accelerated, with a 43% reduction in ulcer area by day 7 (p<0.001) and complete epithelialization observed in 85% of treated eyes by day 14, versus 30% in controls. Furthermore, BPC 157 significantly suppressed corneal neovascularization, showing a 55% decrease in vessel density and length compared to controls (p<0.001). Intraocular pressure was also positively impacted, with treated animals exhibiting a sustained 18% reduction in IOP from baseline by day 14 (p<0.01).